Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 236

1.

Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.

Cadavid D, Jurgensen S, Lee S.

PLoS One. 2013;8(1):e53297. doi: 10.1371/journal.pone.0053297. Epub 2013 Jan 4.

2.

Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.

Zivadinov R, Dwyer MG, Hussein S, Carl E, Kennedy C, Andrews M, Hojnacki D, Heininen-Brown M, Willis L, Cherneva M, Bergsland N, Weinstock-Guttman B.

Mult Scler. 2012 Aug;18(8):1125-34. doi: 10.1177/1352458511433304. Epub 2011 Dec 22.

PMID:
22194217
3.
4.

Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM.

Voloshyna N, Havrdová E, Hutchinson M, Nehrych T, You X, Belachew S, Hotermans C, Paes D.

Eur J Neurol. 2015 Mar;22(3):570-7. doi: 10.1111/ene.12618. Epub 2014 Dec 15.

5.
6.

Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS.

Weinstock-Guttman B, Galetta SL, Giovannoni G, Havrdova E, Hutchinson M, Kappos L, O'Connor PW, Phillips JT, Polman C, Stuart WH, Lynn F, Hotermans C.

J Neurol. 2012 May;259(5):898-905. doi: 10.1007/s00415-011-6275-7. Epub 2011 Oct 19.

PMID:
22008873
8.

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, Sandrock AW, Rudick RA, Simon JH, Simonian NA, Tsao EC, Whitaker JN; IMPACT Investigators.

Neurology. 2002 Sep 10;59(5):679-87.

PMID:
12221157
9.

The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosis.

Cohen JA, Krishnan AV, Goodman AD, Potts J, Wang P, Havrdova E, Polman C, Rudick RA.

JAMA Neurol. 2014 Nov;71(11):1386-93. doi: 10.1001/jamaneurol.2014.1895.

PMID:
25178496
10.

How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?

Brown MG, Kirby S, Skedgel C, Fisk JD, Murray TJ, Bhan V, Sketris IS.

Neurology. 2007 Oct 9;69(15):1498-507. Epub 2007 Aug 15.

PMID:
17699802
11.

Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.

Lanzillo R, Quarantelli M, Bonavita S, Ventrella G, Lus G, Vacca G, Prinster A, Orefice G, Tedeschi G, Brescia Morra V.

Acta Neurol Scand. 2012 Nov;126(5):306-14. doi: 10.1111/j.1600-0404.2011.01622.x. Epub 2011 Nov 23.

PMID:
22107083
12.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
13.

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

Hutchinson M, Kappos L, Calabresi PA, Confavreux C, Giovannoni G, Galetta SL, Havrdova E, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators.

J Neurol. 2009 Mar;256(3):405-15. doi: 10.1007/s00415-009-0093-1. Epub 2009 Mar 18. Erratum in: J Neurol. 2009 Jun;256(6):1035-7.

PMID:
19308305
14.

Natural history of secondary-progressive multiple sclerosis.

Tremlett H, Yinshan Zhao, Devonshire V.

Mult Scler. 2008 Apr;14(3):314-24. doi: 10.1177/1352458507084264. Epub 2008 Jan 21.

PMID:
18208898
15.

Clinical characteristics of responders to interferon therapy for relapsing MS.

Waubant E, Vukusic S, Gignoux L, Dubief FD, Achiti I, Blanc S, Renoux C, Confavreux C.

Neurology. 2003 Jul 22;61(2):184-9. Review.

PMID:
12874396
16.

Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis.

Belachew S, Phan-Ba R, Bartholomé E, Delvaux V, Hansen I, Calay P, Hafsi KE, Moonen G, Tshibanda L, Vokaer M.

Eur J Neurol. 2011 Feb;18(2):240-5. doi: 10.1111/j.1468-1331.2010.03112.x.

PMID:
20561044
17.

Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.

Sanford M, Lyseng-Williamson KA.

Drugs. 2011 Oct 1;71(14):1865-91. doi: 10.2165/11207540-000000000-00000. Review.

PMID:
21942977
18.

A reassessment of the plateauing relationship between T2 lesion load and disability in MS.

Sormani MP, Rovaris M, Comi G, Filippi M.

Neurology. 2009 Nov 10;73(19):1538-42. doi: 10.1212/WNL.0b013e3181c06679. Epub 2009 Sep 30.

PMID:
19794123
19.

History of modern multiple sclerosis therapy.

Lublin F.

J Neurol. 2005 Sep;252 Suppl 3:iii3-iii9. Review.

PMID:
16170498
20.

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.

Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Skoromets A, Stolyarov I, Bass A, Sullivan H, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA.

Neurology. 2012 Apr 3;78(14):1069-78. doi: 10.1212/WNL.0b013e31824e8ee7. Epub 2012 Mar 21.

PMID:
22442431
Items per page

Supplemental Content

Write to the Help Desk